Do analysts rate ATYR or BFRI?

aTyr Pharma currently has a consensus target price of $17.00, suggesting a potential upside of 2,655.27%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe aTyr Pharma is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, ATYR or BFRI?

Biofrontera has higher revenue and earnings than aTyr Pharma. Biofrontera is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio aTyr Pharma $190K 318.40 -$74.12M -$0.73 N/A Biofrontera $41.71M 0.31 -$10.54M -$0.97 N/A

Is ATYR or BFRI more profitable?

aTyr Pharma has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. aTyr Pharma's return on equity of -100.14% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -100.14% -73.55% Biofrontera -25.66% -515.34% -53.91%

Do analysts rate TCRT or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate BFRI or DWTX?

Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 654.72%. Given Dogwood Therapeutics' higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer BFRI or MREO?

Mereo BioPharma Group has a consensus price target of $3.25, suggesting a potential upside of 906.19%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mereo BioPharma Group 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer BFRI or TIL?

Instil Bio has a consensus target price of $66.00, indicating a potential upside of 756.03%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is BFRI or TIL more profitable?

Instil Bio has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Instil Bio's return on equity of -39.76% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Biofrontera -25.66% -515.34% -53.91% Instil Bio N/A -39.76% -22.38%

Biofrontera (BFRI) Competitors

$1.00 +0.06 (+5.87%)

As of 12:34 PM Eastern

Compare

BFRI vs. ATYR, TCRT, DWTX, MREO, and TIL

Should you buy Biofrontera stock or one of its competitors? MarketBeat compares Biofrontera with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biofrontera include aTyr Pharma (ATYR), Alaunos Therapeutics (TCRT), Dogwood Therapeutics (DWTX), Mereo BioPharma Group (MREO), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry.

How does Biofrontera compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

aTyr Pharma has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. aTyr Pharma's return on equity of -100.14% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Biofrontera	-25.66%	-515.34%	-53.91%

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by insiders. Comparatively, 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

aTyr Pharma has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

aTyr Pharma currently has a consensus target price of $17.00, suggesting a potential upside of 2,655.27%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe aTyr Pharma is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biofrontera has higher revenue and earnings than aTyr Pharma. Biofrontera is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	318.40	-$74.12M	-$0.73	N/A
Biofrontera	$41.71M	0.31	-$10.54M	-$0.97	N/A

In the previous week, aTyr Pharma had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for aTyr Pharma and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.87 beat aTyr Pharma's score of 0.76 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Overall Sentiment
aTyr Pharma	Positive
Biofrontera	Very Positive

Summary

aTyr Pharma beats Biofrontera on 10 of the 16 factors compared between the two stocks.

How does Biofrontera compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alaunos Therapeutics has a beta of -1.07, suggesting that its stock price is 207% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

Alaunos Therapeutics has higher earnings, but lower revenue than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
Biofrontera	$41.71M	0.31	-$10.54M	-$0.97	N/A

Alaunos Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Alaunos Therapeutics' return on equity of -165.94% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Biofrontera	-25.66%	-515.34%	-53.91%

In the previous week, Alaunos Therapeutics had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for Alaunos Therapeutics and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.87 beat Alaunos Therapeutics' score of 0.65 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Overall Sentiment
Alaunos Therapeutics	Positive
Biofrontera	Very Positive

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Alaunos Therapeutics and Biofrontera tied by winning 7 of the 14 factors compared between the two stocks.

How does Biofrontera compare to Dogwood Therapeutics?

Biofrontera (NASDAQ:BFRI) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Biofrontera has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 654.72%. Given Dogwood Therapeutics' higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biofrontera has higher revenue and earnings than Dogwood Therapeutics. Biofrontera is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.31	-$10.54M	-$0.97	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.87 beat Dogwood Therapeutics' score of 0.93 indicating that Biofrontera is being referred to more favorably in the media.

Company	Overall Sentiment
Biofrontera	Very Positive
Dogwood Therapeutics	Positive

Dogwood Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Dogwood Therapeutics' return on equity of -108.57% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 8.1% of Biofrontera shares are held by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Dogwood Therapeutics beats Biofrontera on 7 of the 13 factors compared between the two stocks.

How does Biofrontera compare to Mereo BioPharma Group?

Biofrontera (NASDAQ:BFRI) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Biofrontera has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.31	-$10.54M	-$0.97	N/A
Mereo BioPharma Group	$500K	103.11	-$41.88M	-$0.05	N/A

Mereo BioPharma Group has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Mereo BioPharma Group's return on equity of -81.28% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biofrontera has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

Mereo BioPharma Group has a consensus price target of $3.25, suggesting a potential upside of 906.19%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Mereo BioPharma Group had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for Mereo BioPharma Group and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.87 beat Mereo BioPharma Group's score of 1.44 indicating that Biofrontera is being referred to more favorably in the media.

Company	Overall Sentiment
Biofrontera	Very Positive
Mereo BioPharma Group	Positive

Summary

Mereo BioPharma Group beats Biofrontera on 9 of the 16 factors compared between the two stocks.

How does Biofrontera compare to Instil Bio?

Biofrontera (NASDAQ:BFRI) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Biofrontera has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

In the previous week, Biofrontera and Biofrontera both had 1 articles in the media. Biofrontera's average media sentiment score of 1.87 equaled Instil Bio'saverage media sentiment score.

Company	Overall Sentiment
Biofrontera	Very Positive
Instil Bio	Very Positive

Instil Bio has a consensus target price of $66.00, indicating a potential upside of 756.03%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Biofrontera has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.31	-$10.54M	-$0.97	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

Instil Bio has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Instil Bio's return on equity of -39.76% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Instil Bio	N/A	-39.76%	-22.38%

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by company insiders. Comparatively, 47.0% of Instil Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Instil Bio beats Biofrontera on 7 of the 13 factors compared between the two stocks.

Get Biofrontera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BFRI vs. The Competition

Export

Metric	Biofrontera	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.99M	$3.66B	$6.81B	$12.57B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-1.05	21.44	27.52	25.33
Price / Sales	0.31	339.00	539.41	102.00
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	1.13	8.75	10.94	6.61
Net Income	-$10.54M	$23.87M	$3.57B	$336.72M
7 Day Performance	1.51%	3.51%	2.69%	2.63%
1 Month Performance	6.37%	3.56%	1.84%	0.24%
1 Year Performance	47.53%	67.21%	36.35%	29.97%

Biofrontera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BFRI Biofrontera	1.5831 of 5 stars	$1.00 +5.9%	N/A	+32.9%	$12.79M	$41.71M	N/A	70	Positive News Analyst Downgrade Gap Up
ATYR aTyr Pharma	3.4786 of 5 stars	$0.56 +4.5%	$17.00 +2,927.6%	-88.2%	$52.66M	$190K	N/A	53
TCRT Alaunos Therapeutics	0.9409 of 5 stars	$2.15 flat	N/A	-53.4%	$52.51M	N/A	N/A	40
DWTX Dogwood Therapeutics	3.261 of 5 stars	$1.51 -2.6%	$12.00 +694.7%	-66.2%	$52.13M	N/A	N/A	5	News Coverage
MREO Mereo BioPharma Group	3.7139 of 5 stars	$0.30 -5.6%	$3.25 +968.4%	-88.3%	$51.44M	$500K	N/A	40	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BFRI) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biofrontera (BFRI) Competitors

BFRI vs. ATYR, TCRT, DWTX, MREO, and TIL

How does Biofrontera compare to aTyr Pharma?

Summary

How does Biofrontera compare to Alaunos Therapeutics?

Summary

How does Biofrontera compare to Dogwood Therapeutics?

Summary

How does Biofrontera compare to Mereo BioPharma Group?

Summary

How does Biofrontera compare to Instil Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biofrontera (BFRI) Competitors

BFRI vs. ATYR, TCRT, DWTX, MREO, and TIL

How does Biofrontera compare to aTyr Pharma?

Is ATYR or BFRI more profitable?

Do institutionals & insiders believe in ATYR or BFRI?

Which has more risk and volatility, ATYR or BFRI?

Do analysts rate ATYR or BFRI?

Which has better earnings and valuation, ATYR or BFRI?

Does the media favor ATYR or BFRI?

Summary

How does Biofrontera compare to Alaunos Therapeutics?

Do analysts rate TCRT or BFRI?

Which has more volatility and risk, TCRT or BFRI?

Which has stronger earnings and valuation, TCRT or BFRI?

Is TCRT or BFRI more profitable?

Does the media refer more to TCRT or BFRI?

Do insiders & institutionals believe in TCRT or BFRI?

Summary

How does Biofrontera compare to Dogwood Therapeutics?

Which has more risk and volatility, BFRI or DWTX?

Do analysts rate BFRI or DWTX?

Which has higher valuation and earnings, BFRI or DWTX?

Does the media favor BFRI or DWTX?

Is BFRI or DWTX more profitable?

Do insiders and institutionals have more ownership in BFRI or DWTX?

Summary

How does Biofrontera compare to Mereo BioPharma Group?

Which has preferable earnings and valuation, BFRI or MREO?

Is BFRI or MREO more profitable?

Do insiders & institutionals hold more shares of BFRI or MREO?

Which has more risk and volatility, BFRI or MREO?

Do analysts prefer BFRI or MREO?

Does the media refer more to BFRI or MREO?

Summary

How does Biofrontera compare to Instil Bio?

Which has more volatility & risk, BFRI or TIL?

Does the media prefer BFRI or TIL?

Do analysts prefer BFRI or TIL?

Which has stronger earnings & valuation, BFRI or TIL?

Is BFRI or TIL more profitable?

Do institutionals and insiders believe in BFRI or TIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools